💡 𝟖𝟎𝟎 𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥𝐬 joined the EFSPI (European Federation of Statisticians in the Pharmaceutical Industry) Regulatory Statistics Workshop in Basel to hear from One2Treat Founder Marc Buyse and Senior Trial Design Lead Samuel Salvaggio, PhD on “𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐏𝐫𝐨𝐜𝐞𝐝𝐮𝐫𝐞𝐬 𝐟𝐨𝐫 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 & 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬.” 🔍 Regulators challenged the team: “𝐇𝐨𝐰 𝐝𝐨 𝐲𝐨𝐮 𝐞𝐱𝐩𝐥𝐚𝐢𝐧 𝐭𝐡𝐢𝐬 (𝐭𝐡𝐞 𝐍𝐞𝐭 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐁𝐞𝐧𝐞𝐟𝐢𝐭) 𝐭𝐨 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬?” Marc responded with a smile: “𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐞𝐯𝐞𝐫 𝐭𝐫𝐢𝐞𝐝 𝐞𝐱𝐩𝐥𝐚𝐢𝐧𝐢𝐧𝐠 𝐭𝐡𝐞 𝐡𝐚𝐳𝐚𝐫𝐝 𝐫𝐚𝐭𝐢𝐨 𝐭𝐨 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬?” 😎 Curious about the Net Treatment Benefit and how it can make clinical outcomes easier to understand? 👉 Visit our website or get in touch to learn more: www.one2treat.com #ClinicalTrials #Statistics #EFSPI
About us
One2Treat is a forward-thinking partner for biopharmaceutical companies, dedicated to delivering transformative insights in clinical trial design, analysis, and market access evaluations to support holistic treatment decisions. One2Treat was founded in July 2023 after four years of advanced Research and Software Development incubation within IDDI Group. Driven by a commitment to patient-centricity, One2Treat leverages modern statistical methodologies and advanced software solutions, ushering in a new era of personalized healthcare.
- Website
-
www.one2treat.com
External link for One2Treat
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Louvain-la-Neuve
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
Louvain-la-Neuve, BE
Employees at One2Treat
Updates
-
Next week, we’ll be at the 14th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference in Philadelphia. Our CEO Sébastien Coppe, PhD and CMO Pascal Piedbois are joining 800+ industry leaders to explore disruptive advancements in clinical research. We’re eager to showcase how our patient-focused methodologies and innovative software are transforming the way treatments are evaluated—bringing a more holistic approach to clinical trials! 🚀 Are you attending? Get in touch! #patientfocus #ClinicalResearch #Innovation
-
On the road again! Next week, the One2Treat team is heading to Basel for the 9th Annual EFSPI (European Federation of Statisticians in the Pharmaceutical Industry) Regulatory Statistics Workshop, taking place from September 11th to 13th. 📅 This workshop unites stakeholders from industry, academia, and regulatory agencies for valuable discussions on key topics in clinical research. Marc Buyse and Samuel Salvaggio, PhD will present on “𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐏𝐫𝐨𝐜𝐞𝐝𝐮𝐫𝐞𝐬 𝐟𝐨𝐫 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬,” offering insights and solutions for controlling type I error in these complex situations. Looking forward to engaging with regulatory representatives and sharing our expertise!
-
The One2Treat team is back from 4 insightful days in London at #ESCCongress 2024 and they have recorded a short video to share their key takeaways with you! • 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 is becoming more a rule than an exception in cardiology - Pascal Piedbois • Measuring time to worst event can more completely capture the 𝗵𝗼𝗹𝗶𝘀𝘁𝗶𝗰 𝗻𝗲𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 than time to first event - Samuel Salvaggio, PhD • One2Treat can contribute to this long awaited and powerful way to assess treatment effects - Sébastien Coppe, PhD Get in touch to learn more about our solutions ➡️ https://lnkd.in/eJNtnAVU Interested in joining our team? ➡️ https://lnkd.in/eAuPYcAD #ClinicalTrials #Patientfocuseddrugdevelopment #Cardiology
-
A note from our CEO Sébastien Coppe, PhD after 1 year at One2Treat. Happy anniversary 🎉 Here's to the coming years!
One year ago, I embarked on an exciting journey at One2Treat, the most recent disruptive venture led by Marc Buyse. From day one, I’ve been passionate about our mission to provide a reliable, quantitative, and multidimensional assessment of treatment effects. While randomized clinical trials are crucial in evaluating treatment benefits, it’s surprising that in 2024, the majority of studies still focuses on a single primary endpoint — sometimes overlooking the full spectrum of what truly matters to patients and physicians. Over the past 12 months, I’ve had the privilege of learning and growing alongside incredible colleagues and partners. I’ve seen our software evolve, contributed to clinical trial designs that received regulatory approval across various therapeutic areas (including #cv, #rarediseases, #oncology, and #CNS), and refined our strategy to drive this paradigm shift toward more holistic treatment decision-making. These last few days at the congress of the European Society of Cardiology have only reinforced my conviction that pharma companies are eager to incorporate multiple patient-relevant outcomes into single, holistic assessments, both for clinical trial designs and for strategic market access and HTA decisions. As regulatory agencies share the same goal, I’m more enthusiastic than ever to strive for our One2Treat mission and drive change (e.g. FDA guidance on “Patient-Focused Drug Development”, #Optimus project). A huge thank you to everyone who has provided feedback, guided us on this journey, and to all our customers who have trusted us to help them in their patient-focused clinical research. Looking forward to what the next year will bring! 🚀
-
💡We're thrilled to have played a part in the SHAPERS trial, aiming to demonstrate that a less intensive treatment for elderly patients with rectal cancer still provides an overall benefit. For the trial design, One2Treat leveraged 𝐠𝐞𝐧𝐞𝐫𝐚𝐥𝐢𝐳𝐞𝐝 𝐩𝐚𝐢𝐫𝐰𝐢𝐬𝐞 𝐜𝐨𝐦𝐩𝐚𝐫𝐢𝐬𝐨𝐧𝐬, an innovative statistical methodology to estimate the benefit-risk profile of the treatment effect in one 𝐬𝐢𝐧𝐠𝐥𝐞 𝐡𝐨𝐥𝐢𝐬𝐭𝐢𝐜 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭. 🚀 This methodology allowed to 𝐬𝐡𝐢𝐟𝐭 𝐟𝐫𝐨𝐦 𝐝𝐞𝐦𝐨𝐧𝐬𝐭𝐫𝐚𝐭𝐢𝐧𝐠 𝐧𝐨𝐧-𝐢𝐧𝐟𝐞𝐫𝐢𝐨𝐫𝐢𝐭𝐲 𝐭𝐨 𝐬𝐮𝐩𝐞𝐫𝐢𝐨𝐫𝐢𝐭𝐲, therefore significantly 𝐫𝐞𝐝𝐮𝐜𝐢𝐧𝐠 𝐬𝐚𝐦𝐩𝐥𝐞 𝐬𝐢𝐳𝐞. #ClinicalTrials #PatientFocusedDrugDevelopment #PFDD #SHAPERS
📢 The Clinical Trials Center – HUB is thrilled to share an insightful article from Le journal du Médecin / Artsenkrant titled "SHAPERS Study: A New Opportunity for Elderly Patients with Rectal Cancer." The SHAPERS clinical trial represents a significant step forward in providing tailored treatment options for older patients battling rectal cancer. This study emphasizes the importance to improve outcomes and quality of life for a population often underrepresented in clinical research. 🔍 Check out the full article to learn more about how SHAPERS is shaping the future of oncology. FR: https://lnkd.in/dBxSSNmf NL: https://lnkd.in/d3YWWZyc 👨⚕️ Francesco Sclafani Timon Vandamme Tabatha Delsaute KCE Trials 📍 Hôpital Universitaire de Bruxelles (H.U.B) - Academisch Ziekenhuis Brussel (H.U.B) / Institut Jules Bordet #SHAPERS #ClinicalResearch #KCETrials
-
Today the 2024 European Society of Cardiology started in London and One2Treat are well represented with Sébastien Coppe, PhD Samuel Salvaggio, PhD & Pascal Piedbois attending and exhibiting. Come and chat to the team about our ongoing projects, including recent 𝐩𝐡𝐚𝐬𝐞 𝟑 𝐜𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐭𝐫𝐢𝐚𝐥 𝐝𝐞𝐬𝐢𝐠𝐧 where we were able to reduce the sample size by 40% 🔥 ➡️ Join us at Booth F4 #ESCCongress #Cardiovascular #ESC2024 #PatientFocus #PFDD #ClinicalTrials
-
Ahead of the European Society of Cardiology Congress this weekend, we're sharing the high level results from one of our recent 𝐩𝐡𝐚𝐬𝐞 𝟑 𝐜𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐭𝐫𝐢𝐚𝐥 𝐝𝐞𝐬𝐢𝐠𝐧𝐬 with a mid size biotech business. The conventional trial design focused on only one single composite outcome (death from a cardiovascular cause or heart failure). One2Treat's new design includes 𝐟𝐢𝐯𝐞 𝐡𝐢𝐞𝐫𝐚𝐫𝐜𝐡𝐢𝐜𝐚𝐥 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐞𝐱𝐩𝐫𝐞𝐬𝐬𝐞𝐝 𝐛𝐲 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐚𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐛𝐨𝐚𝐫𝐝; Death rate at 2 years, heart-transplant within 2 years, heart-failure related hospitalizations within 2 years, NTproBNP, LVESVi. 𝐓𝐡𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬: Sample size reduced by 40%. Recruitment timelines reduced by 30%. Catch up with Samuel Salvaggio, PhD Sébastien Coppe, PhD & Pascal Piedbois at conference booth F4 to learn more!
-
Curious how One2Treat puts patient interests at the heart of clinical trials? Take just 4 minutes to learn how we integrate all patient-relevant outcomes to fully assess the 𝐧𝐞𝐭 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐛𝐞𝐧𝐞𝐟𝐢𝐭. #patientfocus #PFDD #clinicaltrials #innovationinhealthcare #clinicalresearch #shareddecisionmaking
-
⏰ Just over 1 week until the European Society of Cardiology Congress at ExCeL London from 𝟑𝟎𝐭𝐡 𝐀𝐮𝐠𝐮𝐬𝐭 - 𝟐𝐧𝐝 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫. Pascal Piedbois, Sébastien Coppe, PhD & Samuel Salvaggio, PhD will be representing the One2Treat team. 🙋 Reach out to them to 𝐩𝐥𝐚𝐧 𝐚 𝐜𝐨𝐟𝐟𝐞𝐞 or 𝐝𝐫𝐨𝐩 𝐛𝐲 𝐛𝐨𝐨𝐭𝐡 𝐅𝟒 to learn about how our solutions can help you with 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 whilst 𝐫𝐞𝐝𝐮𝐜𝐢𝐧𝐠 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐧𝐮𝐦𝐛𝐞𝐫𝐬 in clinical trials. #ESCCongress #CardiovascularHealth #ClinicalTrials #InnovationInHealthcare #patientfocus #PFDD #patientfocuseddrugdevelopment #GPC